Mark Emberton, MD, FRCS, presented “Focal Therapy (HIFU): Functional and Oncological Outcomes” for the Grand Rounds in Urology audience in December 2020.
How to cite: Emberton, Mark. “Focal Therapy (HIFU): Functional and Oncological Outcomes” December 2020. Accessed Dec 2024. https://grandroundsinurology.com/focal-therapy-hifu-functional-and-oncological-outcomes/
Summary:
Mark Emberton, MD, FRCS, Professor of Interventional Oncology at University College London, discusses what is and is not known as of 2020 about focal therapy—particularly high intensity focused ultrasound, or HIFU—for localized prostate cancer. He observes that since there is more than a decade’s worth of research behind it, HIFU is hardly experimental anymore, and urologists are by now aware of the therapy’s safety profile, patient selection criteria, short-term outcomes, and medium-term outcomes, with only long-term outcomes still unknown. Dr. Emberton then discusses the goals of focal therapy, the technologies that can or could potentially be used to perform focal therapy, and patient eligibility criteria. He addresses the criticism that focal therapy only treats disease that does not need to be treated, explaining that while this may have been somewhat true in focal therapy’s early conservative years, the era of multiparametric MRI and PSMA PET-CT has made focal therapy more effective, and there exists plenty of research showing that focal therapy is a good alternative treatment that allows patients to maintain continence and erectile function while controlling their cancer. Dr. Emberton concludes by discussing the future of focal therapy, noting that focal therapy programs must embrace stringent quality-control measures, have a true partnership with radiology, have excellent risk stratification, and be committed to long-term follow-up through registries.
ABOUT THE AUTHOR
Mark Emberton, MD, FRCS, is Professor of Interventional Oncology at the University College London. He is an Honorary Consultant Urologist at University College Hospitals NHS Foundation Trust and Founding Pioneer of The Charity Prostate Cancer UK. He was appointed Dean of UCL Faculty of Medical Sciences in 2015.
Professor Emberton’s clinical research is aimed at improving the diagnostic and risk stratification tools and treatment strategies for prostate cancer (PCa). He specializes in the implementation of new imaging techniques, nanotechnologies, bio-engineering materials and non-invasive treatment approaches, such as high intensity focused ultrasound and photo-dynamic therapy.
His research has been published in over 300 peer-reviewed scientific papers in journals including BMJ, Lancet Oncology and European Urology. He has also contributed to the development of guidelines for the management of PCa and lower urinary tract symptoms, published by the International Society of Geriatric Oncology and the European Association of Urology.
Professor Emberton is also involved in teaching within UCL and the London and South East Urological Training scheme. In addition to being a member of various urological and medical organisations (American Association of GenitoUrinary Surgeons, British Association of Urological Surgeons, European Association of Urology). He is a founding partner of London Urology Associates.
